Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay

[1] Paik S(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

[2] Tang G(2015)Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v8-v30

[3] Shak S(2015)Tailoring therapies—improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015 Ann Oncol 26 1533-1546

[4] Kim C(2013)A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK Br J Cancer 108 2250-2258

[5] Baker J(2011)Economic evaluation of the 21-gene signature (Oncotype DX Breast Cancer Res Treat 127 739-749

[6] Kim W(2016)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) Breast Cancer Res Treat 159 315-326

[7] Cronin M(2015)21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013 N Engl J Med 373 2005-2014

[8] Baehner FL(2016)Prospective validation of a 21-gene expression assay in breast cancer J Clin Oncol 34 2341-2349

[9] Watson D(2010)West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment Value Health 13 381-387

[10] Bryant J(2010)Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization J Clin Oncol 28 1671-1676

[1] Paik S(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

[2] Tang G(2015)Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v8-v30

[3] Shak S(2015)Tailoring therapies—improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015 Ann Oncol 26 1533-1546

[4] Kim C(2013)A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK Br J Cancer 108 2250-2258

[5] Baker J(2011)Economic evaluation of the 21-gene signature (Oncotype DX Breast Cancer Res Treat 127 739-749

[6] Kim W(2016)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) Breast Cancer Res Treat 159 315-326

[7] Cronin M(2015)21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013 N Engl J Med 373 2005-2014

[8] Baehner FL(2016)Prospective validation of a 21-gene expression assay in breast cancer J Clin Oncol 34 2341-2349

[9] Watson D(2010)West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment Value Health 13 381-387

[10] Bryant J(2010)Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization J Clin Oncol 28 1671-1676